At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,072 enrolled
Drug / intervention
Cimziadrug
Likely dose
Cimzia 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
In Brief
An observational study evaluating Cimzia for Crohn's Disease. Completed, enrolled 3,072 participants across 197 sites.
Detailed Summary
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedFeb 2009
Primary CompletionAug 2020
TodayJul 2026
First PostedFeb 16, 2009
Enrollment StartJan 30, 2009
Primary CompletionAug 21, 2020
TodayJul 2, 2026
Enrollment to primary: 11.6 yearsPosted 17.4 years ago
Interventions
Cimziadrug
The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.